Coherus to Present Interim Data on Tagmokitug in Esophageal Cancer on October 28
Key Facts
Coherus Oncology said it will present interim clinical data on its tagmokitug program on October 28, 2026, during a webcast hosted by company management from 4:30 to 6:00 p.m. Eastern Daylight Time. The data come from a development program for an investigational drug targeting advanced solid tumors, while the study remains in its early clinical stages. The company said the webcast will allow the data to be discussed and provide additional context. The date marks a presentation of the program's results, while the open material does not contain documented details on patient numbers or response results specific to esophageal cancer. An earlier draft attributed specific response rates to the program, but those figures could not be verified against the original press release.
Coherus describes tagmokitug as a selective cytolytic antibody targeting CCR8 and says it is being studied in Phase 1b/2a trials in patients with advanced solid tumors. The drug is being studied in combination with toripalimab, meaning the anticipated results relate to a combination regimen rather than tagmokitug used alone. The studies identified by the company include squamous cell carcinoma of the head and neck, colorectal cancer, gastric cancer, gastroesophageal junction cancer, esophageal adenocarcinoma and esophageal squamous cell carcinoma. The company's program page says esophageal squamous cell carcinoma is being studied in the first and second lines, while gastric, gastroesophageal junction or esophageal adenocarcinoma is being studied in the second line. This disease scope defines the context for each future result, as findings for one subtype cannot be generalized to all esophageal cancers.
In an earlier second-quarter update, Coherus said the study combining tagmokitug and toripalimab with or without chemotherapy in patients with esophageal squamous cell carcinoma was continuing to enroll participants. The company then expected initial data in the second half of 2026, the period that includes the announced October data presentation. Enrollment progress remains an important part of the program's development, because early results will be assessed in the context of an ongoing study. The company also reported net revenue from continuing operations of $14.3 million in the second quarter of 2026, compared with $10.3 million in the same period of 2025. These figures provide financial context for the company, but do not measure the treatment's efficacy or replace clinical data.
Coherus previously reported, in an early-stage update presented at the AACR meeting in 2025, a confirmed partial response in a patient whose disease was resistant to PD-1-targeted treatment after receiving the tagmokitug and toripalimab combination. The patient had relapsed or metastatic head and neck cancer, not esophageal cancer, so that result remains separate from an assessment of the treatment's activity in esophageal tumors. This background shows that the program has extended to more than one type of solid tumor, with different treatment combinations and disease settings under study. On safety, the available statement summary describes the profile as acceptable and manageable, with no new safety signals to date; however, the company's original wording could not be verified on the open press release page. Details on safety and the results associated with the October presentation therefore remain important to understanding the limits of early signals.
After the data presentation, attention will turn to the company's next milestones. Coherus said its third-quarter 2026 financial results will be released on November 9. That date comes days after the clinical data presentation, but concerns the company's financial disclosure and is not an announced date for an additional clinical readout. The second-quarter update had pointed to initial data from the esophageal squamous cell carcinoma study in the second half of 2026. The data presented by the company, along with enrollment progress and safety information, will remain areas to watch in the development of tagmokitug. Available information does not include a specific date for a larger study or a decision on moving to a later stage.